Glioblastoma (grade IV astrocytoma) is an aggressive primary brain tumor that is extremely difficult to treat.  There is an unmet medical need for treatment as the current prognosis is only 8.7% of patients surviving two years.

The Discovery of CTO


While working as a patent attorney, Dr. Karmali had a client with a promising therapeutic for multiple cancerous indications. The client was interested in evaluating the therapy for prostate cancer.

Clinical Results of CTO


Two recent phase I studies of CTO in a refractory patient populations demonstrated that: CTO is safe and tolerable and has yet to reach MTD at up to 555 mg/m2/day, and therapeutically relevant CAI levels were demonstrated at 219 mg/m2/day dose.